Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 11, 1996, Pages 4013-4021

  Van Teunenbroek, Arne ^a   De Muinck Keizer Schrama, Sabine M P F ^a   Stijnen, Theo ^b   Jansen, Maarten ^c   Otten, Barto J ^d   Delemarre Van De Waal, Henriëtte A ^e   Vulsma, Tom ^f   Wit, Jan Maarten ^g   Rouwé, Catharinus W ^h   Reeser, H Maarten ⁱ   Gosen, Jos J ^j   Rongen Westerlaken, Ciska ^k   Drop, Stenvert L S ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF GRONINGEN   (Netherlands)

ⁱ JULIANA CHILDREN S HOSPITAL   (Netherlands)

^j RIJNLAND HOSPITAL   (Netherlands)

^k CANISIUS WILHELMINA HOSPITAL   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ARTICLE; BONE AGE; BONE MATURATION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GROWTH REGULATION; HORMONE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TURNER SYNDROME;

BODY HEIGHT; BONE DEVELOPMENT; CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GROWTH; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; TIME FACTORS; TURNER SYNDROME;

EID: 10544252272     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.11.4013     Document Type: Article

References (46)

1. Albertsson-Wikland K, Rosberg S. 1991 Pattern of spontaneous growth hormone secretion in Turner syndrome. In: Ranke MB, Rosenfeld R, eds. Turner syndrome: Growth promoting therapies, Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division); 23-28.
2. Wit JM, Massarano AA, Kamp GA, et al. 1992 Growth hormone (GH) secretion in Turner girls as determined by time series analysis. Acta Endocrinol. 127:7-12.
3. Tanaka T, Hibi I, Shizume K. 1991 GH secretion capacity in Turner syndrome and its influence on the effect of GH treatment. In: Ranke MB, Rosenfeld R, eds. Turner syndrome: Growth promoting therapies, Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division): 41-45.
4. Kamp GA, Kuilboer MM, Wynne HJ, et al. 1993 Slow baseline growth and a good response to growth hormone (GH) therapy are related to elevated spontaneous GH pulse frequency in girls with Turner's syndrome. J Clin Endocrinol Metab. 76:1604-1609.
5. Stahnke N, Stubbe P, Attanasio A, Reinhardt D, Partsch CJ, Sippell WG. 1993 GH therapy alone or together with oxandrolone in 212 patients with Turner syndrome (TS): The German experience. In: Hibi I, Takano K, eds. Basic and clinical approach to Turner syndrome, Amsterdam: Elsevier Science Publishers B.V.: 315-322.
6. Chaussain JL, Gendrel C, Job B, Ducret JP. 1993 Optimizing of the dose of growth hormone in girls with Turner syndrome. In: Hibi I, Takano K, eds. Basic and clinical approach to Turner syndrome, Amsterdam: Elsevier Science Publishers B.V.: 273-278.
7. Spoudeas HA, Motta RM, Stanhope R, Hindmarsh PC, Brook CGD. 1993 Therapeutic options for promoting growth in the Turner syndrome. In: Hibi I, Takano K, eds. Basic and clinical approach to Turner syndrome, Amsterdam: Elsevier Science Publishers B.V.: 323-326.
8. Albertsson-Wikland K, Westphal O, Westgren U. 1986 Daily subcutaneous administration of human growth hormone in growth hormone deficient children. Acta Paediatr Scand. 75:89-97.
9. Job JC, Chaussain JL, Garnier P, Rolland A, Joab N. 1987 Dose-response relationship in the treatment of hypopituitary children with human growth hormone: a retrospective survey. Acta Paediatr Scand [Suppl]. 337:93-105.
10. De Muinck Keizer-Schrama S, Rikken B, Hokken-Koelega A, Wit JM, Drop S, the Dutch Growth Hormone Working Group. 1994 Comparative effect of two doses of growth hormone for growth hormone deficiency. Arch Dis Child. 71:12-18.
11. Rongen-Westerlaken C, Wit JM. 1991 Growth hormone therapy in Turner syndrome: the Dutch experience. In: Ranke MB, Rosenfeld R, eds. Turner syndrome: Growth promoting therapies, Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division): 225-229.
12. Rongen-Westerlaken C, Nienhuis HE, Wit JM, et al. 1993 The effect of four years of growth hormone therapy on body stature and proportions in patients with Turner syndrome. In: Hibi I, Takano K, eds. Basic and clinical approach to Turner syndrome, Amsterdam: Elsevier Science Publishers B.V.: 293-302.
13. Nienhuis HE, Rongen-Westerlaken C, Wit JM, et al. 1993 Results of long-term therapy with growth hormone in two dose regimens in Turner syndrome. Horm Res. [Suppl]. 39:31-36.
14. Frasier SD, Costin G, Lippe BM, Aceto Jr T, Hunger PF. 1981 A dose-response curve for human growth hormone. J Clin Endocrinol Metab. 53:1213-1217.
15. Takano K, Shizume K, Hibi I, et al. 1993 Long-term effects of growth hormone on height in Turner syndrome: The result of a 5-year multicentric study in Japan. In: Hibi I, Takano K, eds. Basic and clinical approach to Turner syndrome, Amsterdam: Elsevier Science Publishers B.V.: 333-338.
16. Rongen-Westerlaken C, Wit JM, de Muinck Keizer-Schrama SMPF, et al. 1992 Growth hormone treatment in Turner syndrome accelerates growth and skeletal maturation. Eur J Pediatr. 151:477-481.
17. Rosenfeld RG, the Genentech National Cooperative study group. 1992 Growth hormone therapy in Turner's syndrome: an update on final height. Acta Paediatr [Suppl]. 383:3-6.
18. Gertner JM, Tamborlane WV, Gianfredi SP, Genel M. 1987 Renewed catch-up growth with increased replacement doses of human growth hormone. J Pediatr. 110:425-428.
19. Bundak R, Hindmarsh PC, Smith PJ, Brook CGD. 1988 Long-term auxologic effects of human growth hormone. J Pediatr. 112:875-879.
20. Jörgensen JOL, Flyvbjerg A, Lauritzen T, Alberti KGMM, Örskov H, Christiansen JS. 1988 Dose-response studies with biosynthetic human growth hormone (GH) in GH-deficient patients. J Clin Endocrinol Metab. 67:36-40.
21. Roede MJ, Van Wieringen JC. 1985 Growth diagrams 1980. Netherlands third nationwide survey. Tijdschr Soc Gezondh. [Suppl]. 63:1-34.
22. Tanner JM, Whitehouse RH, 1976 Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child. 51:170-179.
23. Cameron N. 1978 The methods of auxological anthropometry. In: Falkner F, Tanner JM, eds. Human Growth, 2, Postnatal Growth, London: Tindall.
24. Karlberg J, Albertsson-Wikland K, Naeraa RW, Rongen-Westerlaken C, Wit JM. 1993 Reference values for spontaneous growth in Turner girls and its use in estimating treatment effects. In: Hibi I, Takano K, eds. Basic and clinical approach to Turner syndrome, Amsterdam: Elsevier Science Publishers B.V.: 83-92.
25. Rolland-Cachera MF, Sempe M, Guilloud-Bataille M, Patois E, Pequignot-Guggenbuhl F, Fautrad V. 1982 Adiposity indices in children. Am J Clin Nutr. 78:178-184.
26. Tanner JM, Whitehouse RH, Cameron N, Marshall WA, Healy MJR, Goldstein H. 1983 Assessment of skeletal maturity and prediction of adult height (TW2-method). 2nd ed. London: Academic Press.
27. Van Teunenbroek A, de Waal W, Roks A, et al. 1996 Computer Aided Skeletal Age Scores (CASAS) in healthy children, girls with Turner syndrome, and in children with constitutionally tall stature. Pediatr Res. 39:360-367.
28. Lenko HL. 1979 Prediction of adult height with various methods in Finnish children. Acta Paediatr Scand. 68:85-92.
29. Van Teunenbroek A, Stijnen T, Otten B, et al. 1996 A regression method including chronological and bone age for predicting final height in Turner syndrome, with a comparison of existing methods. Acta Paediatr Scand. 85: 413-420.
30. Hokken-Koelega ACS, Hackeng WHL, Stijnen T, Wit JM, de Muinck Keizer-Schrama SMPF, Drop SLS. 1990 24-Hour plasma GH profiles, urinary GH excretion and plasma IGF-I and -II levels in prepubertal children with chronic renal insufficiency and severe growth retardation. J Clin Endocrinol Metab. 71:688-695.
31. Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich JR. 1990 A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab. 70:1292-1298.
32. Van Teunenbroek A, de Muinck Keizer-Schrama SMPF, Stijnen T, et al. 1993 Effect of growth hormone administration frequency on 24-hour growth hormone profiles and levels of other growth related parameters in girls with Turner's syndrome. Clin Endocrinol. 39:77-84.
33. Carlsson LMS, Rowland AM, Clark RG, Gesundheit N, Wong WLT. 1991 Ligand-mediated immunofunctional assay for quantitation of growth hormone-binding protein in human blood. J Clin Endocrinol Metab. 73:1216-1223.
34. Carlsson LMS, Attie KM, Compton PG, Vitangcol RV, Merimee TJ. 1994 Reduced concentration of serum growth hormone-binding protein in children with idiopathic short stature. J Clin Endocrinol Metab. 78:1325-1330.
35. Ranke MB, Blum WF, Haug F, et al. 1987 Growth hormone, somatomedin levels and growth regulation in Turner's syndrome. Acta Endocrinol (Copenh). 116:305-313.
36. Cappa M, Loche S, Borelli P, et al. 1987 Growth hormone response to growth hormone releasing hormone 1-40 in Turner's syndrome. Horm Res. 27:1-6.
37. Ross JL, Long LM, Loriaux DL, Cutler GBJ. 1985 Growth hormone secretory dynamics in Turner syndrome. J Pediatr. 106:202-206.
38. Lin TH, Kirkland JL, Kirkland RT. 1988 Growth hormone assessment and short-term treatment with growth hormone in Turner syndrome. J Pediatr. 112:919-922.
39. Lanes R, Brito S, Suniaga M, Moncada G, Borges M. 1990 Growth hormone secretion in pubertal age patients with Turner's syndrome. J Clin Endocrinol Metab. 71:770-772.
40. Veldhuis JD, Iranmanesh H, Ho KKY, Waters MJ, Johnson ML, Lizarralde G. 1991 Dual effects in pulsatile growth hormone secretion, clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab. 72:51-59.
41. Frisch H, Häusler G, Blümel P, Schmitt K, Tulzer W, Plöchl E. 1991 Relationship of spontaneous nocturnal GH secretion to GH stimulation and the influence of estrogen pretreatment in Turner syndrome. In: Ranke MB, Rosenfeld R, eds. Turner syndrome: Growth promoting therapies, Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division): 35-40.
42. Albertsson-Wikland K. 1986 Growth hormone treatment in short children. Acta Paediatr Scand. 325:64-70.
43. Takano K, Shizume K, Hibi I, the members of the committee for the treatment of Turner's syndrome. 1992 Treatment of 46 patients with Turner's syndrome with recombinant human growth hormone (YM-17798) for three years: a multicentre study. Acta Endocrinol (Copenh). 126:296-302.
44. Ranke MB, Frisch H, Blum WF, Wollmann H, Bruegmann G. 1993 Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) during treatment with growth hormone in Ullrich-Turner syndrome. In: Hibi I, Takano K, eds. Basic and clinical approach to Turner syndrome, Amsterdam: Elsevier Science Publishers B.V.: 239-244.
45. Ranke MB, Blum WF, Frisch H. 1989 The acid-stable subunit of insulin-like growth factor binding protein in disorders of growth. In: Drop SLS, Hintz RL, eds. Insulin-like growth factor binding proteins, Amsterdam: Elsevier Science Publishers B.V.: 103-113.
46. Carlsson LMS, Albertsson-Wikland K. 1993 Growth hormone-binding protein concentration in girls with Turner syndrome: Effects of GH, oxandrolone and ethinyl estradiol. In: Hibi I, Takano K, eds. Basic and clinical approach to Turner syndrome, Amsterdam: Elsevier Science Publishers B.V.: 255-260.